| 摘要 |
The main purpose of the present invention is to provide a novel pharmaceutical composition for oral administration for the treatment of primary tumors in the central nervous system associated with ROS1 tyrosine kinase or cancers metastasized to the central nervous system associated with ROS1 tyrosine kinase. [Solution] A pharmaceutical composition for oral administration for the treatment of primary tumors in the central nervous system associated with ROS1 tyrosine kinase or cancers metastasized to the central nervous system associated with ROS1 tyrosine kinase, which contains, as an active ingredient, a compound represented by general formula [1], a pharmaceutically acceptable salt thereof or a solvate thereof. In the formula, R1 represents a halogen or a phenyl group which may be substituted by one or two groups selected from the group consisting of alkoxy groups and alkyl groups which may be substituted by a halogen; R2 represents a hydrogen atom, an alkyl group which may be substituted by a halogen, a cycloalkyl group, an alkoxy group or a heteroaryl group which may be substituted by an alkyl group; X represents CR3 and Y represents N or CR4, or alternatively X represents N and Y represents CR4; and Z represents CR5 or N. |
